VALNEVA and HOOKIPA Sign a Collaboration and Manufacturing Agreement
December 06 2018 - 11:46AM
Valneva and HOOKIPA Sign a Collaboration and
Manufacturing Agreement
Saint-Herblain, France, and Vienna, Austria,
December 06, 2018 - Valneva Sweden AB, the Swedish subsidiary
of Valneva SE ("Valneva"), and HOOKIPA Pharma Inc. ("HOOKIPA")
today announced that they have entered into a three-year
collaboration and manufacturing agreement.
Under the terms of the agreement, Valneva Sweden
will provide analytical services, develop process scale-up and
produce GMP clinical trial material to support the development of
new immunotherapies based on HOOKIPA's Vaxwave®* and TheraT®*
arenavirus vector- technologies. In return, Valneva will receive
fixed and success-based service fees. The agreement may be extended
beyond three years.
Janet Hoogstraate, Chairman of Valneva
Sweden, commented, "We are excited to collaborate and support
HOOKIPA in its innovative development of novel immunotherapeutics
to help overcome infectious diseases and cancers. This
collaboration is a great recognition of Valneva's strong technical
and industrialization capabilities. Our dedicated Swedish unit has
an excellent track record in development and clinical
manufacturing."
Joern Aldag, Chief Executive Officer of
HOOKIPA, added, "The collaboration with Valneva will
give us access to a dedicated GMP facility and qualified workforce
for the manufacture of clinical trial material according to our
specific needs. It emphasizes our strategy to secure sufficient
manufacturing capacity, reduce cycle times and increase the
robustness and consistency of the process. We look forward to
working with Valneva's great team."
About Valneva SEValneva is a biotech
company developing and commercializing vaccines for infectious
diseases with major unmet needs. Valneva's portfolio includes two
commercial vaccines for travelers: IXIARO®/JESPECT® indicated for
the prevention of Japanese encephalitis and DUKORAL® indicated for
the prevention of cholera and, in some countries, prevention of
diarrhea caused by ETEC. The Company has proprietary vaccines in
development including a unique vaccine against Lyme disease.
Valneva has operations in Austria, Sweden, the United Kingdom,
France, Canada and the US with over 450 employees. More information
is available at www.valneva.com.
About HOOKIPAHOOKIPA Pharma Inc. is a clinical stage
biopharmaceutical company developing a new class of
immunotherapeutics targeting infectious diseases and cancers based
on its proprietary arenavirus platform that is designed to
reprogram the body's immune system.
Our proprietary arenavirus-based technologies,
Vaxwave®*, a replication-deficient viral vector, and TheraT®*, a
replication-attenuated viral vector, are designed to induce robust
antigen specific CD8+ T cells and pathogen-neutralizing antibodies.
Both, Vaxwave® and TheraT®, are designed to allow for repeat
administration while maintaining an immune response. TheraT®* has
the potential to induce CD8+ T cell response levels previously not
achieved by other published immuno-therapy approaches. Our
"off-the-shelf" viral vectors target dendritic cells in vivo to
activate the immune system.
We have successfully completed a Phase 1 trial
of a Vaxwave®-based prophylactic vaccine to protect against
cytomegalovirus infection. We have initiated enrollment for a Phase
2 trial in cytomegalovirus-negative patients awaiting kidney
transplantation from cytomegalovirus-positive donors. To expand our
infectious disease portfolio, we have entered into a collaboration
and licensing agreement with Gilead Sciences, Inc. to jointly
research and develop functional cures for HIV and Hepatitis B
infections. We are building a proprietary immuno-oncology pipeline
by targeting virally mediated cancer antigens, self-antigens and
next-generation antigens.
Find out more about HOOKIPA online at
www.hookipapharma.com.
*Registered in Europe; Pending in the US.
Investor and Media Contacts
Valneva Laetitia
Bachelot-FontaineGlobal Head of Investor Relations & Corporate
CommunicationsM +33 (0)6 4516 7099investors@valneva.com |
Teresa
PinzolitsCorporate Communications SpecialistT +43 (0)1 20620
1116communications@valneva.com |
HOOKIPANina
Waibel
Marine PopoffHead of Communications
Communications & IR Manager
Nina.Waibel@HookipaPharma.com
Marine.Popoff@HookipaPharma.com
Media enquiries (for HOOKIPA)Sue Charles/
Ashley TappInstinctif PartnersHookipa@Instinctif.com+44 (0)20 7457
2020
Valneva Forward-Looking StatementsThis
press release contains certain forward-looking statements relating
to the business of Valneva, including with respect to the progress,
timing and completion of research, development and clinical trials
for product candidates, the ability to manufacture, market,
commercialize and achieve market acceptance for product candidates,
the ability to protect intellectual property and operate the
business without infringing on the intellectual property rights of
others, estimates for future performance and estimates regarding
anticipated operating losses, future revenues, capital requirements
and needs for additional financing. In addition, even if the actual
results or development of Valneva are consistent with the
forward-looking statements contained in this press release, those
results or developments of Valneva may not be indicative of the
future. In some cases, you can identify forward-looking statements
by words such as "could," "should," "may," "expects,"
"anticipates," "believes," "intends," "estimates," "aims,"
"targets," or similar words. These forward-looking statements are
based largely on the current expectations of Valneva as of the date
of this press release and are subject to a number of known and
unknown risks and uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from any future results, performance or achievement
expressed or implied by these forward-looking statements. In
particular, the expectations of Valneva could be affected by, among
other things, uncertainties involved in the development and
manufacture of vaccines, unexpected clinical trial results,
unexpected regulatory actions or delays, competition in general,
currency fluctuations, the impact of the global and European credit
crisis, and the ability to obtain or maintain patent or other
proprietary intellectual property protection. In light of these
risks and uncertainties, there can be no assurance that the
forward-looking statements made in this press release will in fact
be realized. Valneva is providing the information in these
materials as of the date of this press release, and disclaims any
intention or obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
- 2018_12_06_VLA_Hookipa_Collaboration_PR_EN.pdf
Valneva (EU:VLA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Valneva (EU:VLA)
Historical Stock Chart
From Sep 2023 to Sep 2024